Trevena and Forest Labs collaborate on TRV027 for acute heart failure The Pharma Letter Trevena expects to commence a 500-patient multicenter Phase IIb clinical trial in acute decompensated heart failure (ADHF) by year end. Specific terms of the transaction were not disclosed but the agreement includes a $30 million equity investment by ... Forest Labs Bets Up To $460M on Trevena Heart Failure Drug Trevena Raises $60M Series C, Strikes $430M Option Deal With Forest Labs Trevena lands $430M Forest deal, $60M venture round as heart drug heads to ... |
